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This study used a prospectively managed clinical database in order to identify 1470 patients with gastrointestinal cancers receiving
protracted venous infusion (PVI) fluorouracil (5FU). It aimed to determine the time course of toxicity due to PVI 5FU and to analyse
factors predicting toxicity. The initial development of stomatitis occurred more rapidly than diarrhoea or palmar plantar erythema
(PPE). The percentage of patients with National Cancer Institute Common Toxicity Criteria (CTC) grade 2 or worse PPE peaked at
9% between weeks 8 and 17, whereas this peak occurred earlier for stomatitis and diarrhoea. The development of CTC grade 1
toxicity in the first 28 days after commencement of chemotherapy was classified as early grade 1 toxicity. Multivariate Cox regression
analysis showed that female sex, better performance status, elevated bilirubin, early grade 1 PPE and early grade 1 diarrhoea were
independent prognostic factors for the development of CTC grade 2 or worse PPE (Po0.01). Female sex, increased age, elevated
alanine transaminase and urea and early grade 1 PPE were significant independent prognostic factors for the development of CTC
grade 2 or worse stomatitis (Po0.01). Early CTC grade 1 diarrhoea predicted CTC grade 2 or worse diarrhoea (Po0.01). Older,
female patients with good performance status and impaired liver and renal function who develop early grade 1 PPE alone or in
combination with diarrhoea are at highest risk of subsequently developing grade 2 or worse PPE or stomatitis during treatment with
PVI 5FU. Reduction of infused 5FU dose should be considered for these patients. Such an approach could both reduce severe toxicity
owing to chemotherapy and minimise treatment delays, and should be evaluated prospectively.
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Fluorouracil (5FU)-based chemotherapy is used for the adjuvant
and palliative treatment of a variety of different tumour types,
particularly for gastrointestinal cancers. A recent meta-analysis
demonstrated that the efficacy of 5FU was dependent on its
schedule of administration. Infused schedules of 5FU resulted in
superior response rates with a small but statistically significant
prolongation of survival in advanced colorectal cancer compared
with bolus schedules (Meta-analysis Group In Cancer, 1998a). In
addition, the toxicity profile of infused 5FU differs from bolus
schedules. Infused 5FU results in similar incidences of diarrhoea
and stomatitis, but causes a lower incidence of haematological
toxicity and a higher incidence of palmar–plantar erythema (PPE).
Thus, diarrhoea, stomatitis and PPE form the most frequent and
the dose-limiting toxicities for infused 5FU (Meta-analysis Group
In Cancer, 1998b).
The development of chemotherapy-induced toxicity has an
adverse impact on quality of life and in the most severe cases may
cause death during treatment. The management of toxicities owing
to chemotherapy are generally made on an empirical basis only
after the development of dose-limiting side effects and generally
involve interruption of chemotherapy and dose reduction in order
to prevent future episodes. This study aimed to analyse the
principal dose-limiting toxicities of infused 5FU therapy observed
in a large cohort of patients treated at a single centre. It aimed to
identify clinical, laboratory and temporal factors, which could be
combined in order to identify those patients who were at greatest
risk of toxicity.
PATIENTS AND METHODS
Patients and toxicity assessment
The Gastrointestinal Unit (GI unit) at the Royal Marsden Hospital
(RMH) has maintained a prospective database of all patients
receiving chemotherapy. This database contains details of baseline
demographic data, haematological and biochemical parameters,
chemotherapy administration, tumour response to chemotherapy
and survival and toxicity data graded according to the National
Cancer Institute Common Toxicity Criteria version 1 (Macdonald
et al, 1995). Toxicities were recorded on a weekly basis for patients
receiving infused 5FU regimens. Diarrhoea, PPE and stomatitis
were selected as the toxicities to study, as these are the most
frequent and dose-limiting side-effects of infused 5FU.
Chemotherapy
Patients were eligible for this analysis if they had received
protracted venous infusion (PVI) 5FU 300mgm
 2day
 1 alone or
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 2day
 1 and bolus Mitomycin C (MMC) 7mg/
m
2 q 6 weekly. MMC is associated with a mild and predominantly
haematological toxicity profile; consequently in patients receiving
MMC with PVI 5FU, the toxicities of diarrhoea, PPE and stomatitis
were considered to most likely result from 5FU (DeVita et al,
1993). Patients receiving any other chemotherapy or concurrent
radiotherapy were excluded from this analysis, as these other
treatments would be likely to affect diarrhoea or stomatitis.
Treatment with PVI 5FU with or without MMC was continued
up to 24 weeks, unless patients developed progressive disease or
excessive toxicity.
Empirical management of toxicity
Nonhaematological toxicities developing during PVI 5FU therapy
were managed uniformly as follows. Grade 1 stomatitis and
diarrhoea were treated with oral sucralfate and codeine phosphate,
respectively, and grade 1 PPE was treated with oral pyridoxine. No
dose reduction or delay of 5FU was made for grade 1 toxicities.
Grade 2 or worse nonhaematological toxicities led to cessation of
5FU treatment until resolution of toxicity followed by a dose
reduction of 5FU except for PPE developing for the first time after
10 weeks of therapy, where treatment was initially recommended at
the original starting dose. Otherwise, grade 2 toxicities led to a
50mgm
 2 dose reduction, grade 3 toxicities to 100mgm
 2 dose
reduction and grade 4 toxicities to 150 mgm
 2 dose reduction.
Therefore, for this analysis dose-limiting toxicities were defined as
grade X2 toxicities as this severity of toxicity would usually result
in a dose reduction.
Statistical methods
Time to the development of toxicity was calculated using the
inverted methods of Kaplan and Meier (1958). Multivariate Cox
regression analysis was used to generate multivariate proportional
hazards models based on times to events as stated in the results.
Factors included in the analyses were clinical factors (age, sex,
performance status, type of primary tumour, presence of meta-
static disease, chemotherapy arm), biochemical parameters (liver
and renal function) and temporal factors. Hazard ratios associated
with continuous variables other than age were not proportional
across the full range of the variable. Therefore, continuous
variables other than age were grouped as categorical values based
on the median value of the variable. P-values of less than 0.01 were
considered significant.
RESULTS
Patient demographics and overall toxicity
Between January 1994 and January 2001, 1470 patients with
gastrointestinal cancer received treatment using infused 5FU at the
Royal Marsden Hospital (RMH). The baseline demographics of
these patients are shown in Table 1. The percentage of patients
who developed diarrhoea, PPE or stomatitis at any time during
treatment is shown in Table 2. However, these data provide no
information relating to when the toxicity occurred or which
patients were at greatest risk of developing toxicity.
Time course of initial development of toxicity
Figures 1A–3A demonstrate the time to the first development of
varying grades of diarrhoea, PPE and stomatitis for patients
receiving chemotherapy. The baseline was defined as the date of
commencement of chemotherapy and the events were the grades of
toxicities encountered. The denominator at each time point was
the number of patients receiving chemotherapy at that time and
patients were censored at the chemotherapy stop date if no toxicity
was encountered. The stepped profile of these curves reflects the
weekly collection of toxicity data. Small numbers of patients
continued treatment beyond 24 weeks as a result of previous
treatment interruptions due to prior toxicities. The time course for
the development of these three individual toxicities varied
according to the toxicity. Thus, the initial development of
stomatitis frequently occurred soon after commencement of
chemotherapy, whereas the initial development of diarrhoea and
PPE was more gradual with many cases occurring for the first time
towards the end of therapy.
Proportion of patients with dose-limiting toxicities during
treatment
The time course of grade 2 or worse toxicities was studied in
further detail, as this severity usually required modification of
chemotherapy dose. The proportion of patients with grade 2 or
worse diarrhoea, PPE and stomatitis was therefore determined
during each week of chemotherapy. These results depict both
initial as well as subsequent episodes of grade 2 or worse toxicities
for all patients who were continuing to receive chemotherapy. The
denominator at each time point was the number of patients
receiving chemotherapy at that time. The percentage of patients
with grade 2 or worse diarrhoea peaked at about 4.5% between
weeks 5 and 8. Approximately 30% of patients with grade 2 or
worse diarrhoea also had another grade 2 or worse toxicity
(Figure 1B). The percentage of patients with grade 2 or worse PPE
peaked at about 9% between weeks 8 and 17, and the majority of
these patients had grade 2 or worse PPE alone without any other
toxicity (Figure 2B). The percentage of patients with grade 2 or
worse stomatitis peaked between weeks 4 and 6, with approxi-
mately 30% of patients also suffering another grade 2 or worse
toxicity (Figure 3B).
Table 1 Baseline demographics of patients treated with PVI 5FU
Number Percentage
Total 1470 100.0
PVI 5FU alone 861 58.6
PVI 5FU plus MMC 609 41.4
Male 833 56.7
Female 637 43.3
Performance status 0–1 1081 73.6
Performance status 2–3 364 24.8
Unknown performance status 25 1.7
Age: median (range) 64 (24–86)
Palliative treatment 1131 76.9
Adjuvant treatment 339 23.1
Primary tumour
Oesophago-gastric 172 11.7
Colorectal 955 65.0
Pancreas 245 16.7
Unknown primary 98 6.7
Table 2 Percentage of patients with varying grades of toxicity
Grade of toxicity
012 3 4
Diarrhoea 58.4 23.2 13.1 3.6 1.7
PPE 37.1 28.0 28.0 6.9
Stomatitis 51.3 21.5 21.7 4.3 1.2
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lIdentification of early grade 1 toxicities
While the development of more severe toxicities led to a dose delay
or dose reduction, the development of individual grade 1 toxicities
alone did not mandate any dose modification. The risk of
developing a worse grade toxicity after the development of an
initial grade 1 toxicity was analysed in more detail, in order to
assess whether the time of onset of grade 1 toxicity had any
prognostic significance for the subsequent development of more
severe toxicity. Univariate Cox regression analysis demonstrated
that each extra day after commencing chemotherapy before the
development of a grade 1 toxicity resulted in a lower risk of
subsequently developing a grade 2 or worse toxicity in the case of
PPE (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.985–
0.994; Po0.001) and stomatitis (HR 0.965, 95% CI 0.95–0.98;
Po0.001). This result suggested that the time at which grade 1
toxicity initially developed could be used to identify patients who
were at higher risk of subsequently developing a more severe
toxicity.
The median time until the first development of any grade 1
toxicity was 28 days. Patients with early grade 1 toxicities were
therefore defined as those patients who developed grade 1 but not
grade 2 or worse diarrhoea, PPE or stomatitis before completing 28
days of chemotherapy. This time point also predates the times at
which the largest proportions of patients have grade 2 or worse
toxicities (see Figures 1B–3B).
In all, 55.1% of patients with early grade 1 PPE subsequently
developed grade 2 or worse PPE compared with 27.3% of patients
without early grade 1 PPE (Po0.001). A total of 19.9% of patients
with early grade 1 diarrhoea subsequently developed grade 2 or
worse diarrhoea compared with 11.9% of patients without early
grade 1 diarrhoea (P¼0.003). Totally, 19.5% of patients with early
grade 1 stomatitis subsequently developed grade 2 or worse
stomatitis compared with 11.4% of patients without early grade 1
stomatitis (P¼0.003).
Multivariate Cox regression analysis of baseline and
temporal factors associated with toxicities
The significance of early grade 1 toxicity in addition to
other clinical and laboratory parameters as prognostic
factors associated with the development of more severe
toxicity was examined using multivariate Cox regression
analysis (see Table 3). Early grade 1 diarrhoea predicted grade 2
or worse diarrhoea. Female sex, good performance status, elevated
bilirubin, early grade 1 PPE and early grade 1 diarrhoea were
independent prognostic factors for the development of grade 2 or
worse PPE. Female sex, increased age, ALT, urea and early grade 1
PPE were independent prognostic factors for the development of
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Figure 1 (A) Time until initial development of varying grades of
diarrhoea. (B) Proportion of patients receiving PVI 5FU with grade 2 or
worse diarrhoea. Closed columns indicate patients with only grade X2
diarrhoea, whereas open columns indicate patients with grade X2
diarrhoea and grade X2 stomatitis and/or PPE.
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Figure 2 (A) Time until initial development of varying grades of PPE. (B)
Proportion of patients receiving PVI 5FU with grade 2 or worse PPE.
Closed columns indicate patients with only grade X2 PPE, whereas open
columns indicate patients with grade X2 PPE and grade X2 diarrhoea and/
or stomatitis.
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lgrade 2 or worse stomatitis. No other factors including primary
tumour site and chemotherapy arm were significantly associated
with toxicity.
Identification of patients at high risk of toxicity
The multivariate Cox regression analysis allows identification of
subgroups of patients at higher risk of toxicity with PVI 5FU.
Based on the multivariate Cox regression analysis, older, female
patients with good performance status, impaired liver function
(alanine transaminase; ALTX16Ul
 1 or bilirubinX12mmoll
 1)
and renal function (ureaX4.8mmol/l
 1) who develop early grade 1
PPE alone or in combination with diarrhoea could be considered
for early dose reduction, at the time of development of early
toxicity, as this group of patients is at the highest risk of grade 2 or
worse PPE and stomatitis.
DISCUSSION
This study represents the largest analysis of the toxicities
associated with infused 5FU and provides information about the
development of toxicities with time and evaluation of factors
predicting the development of moderate and severe toxicity. A
previous meta-anlysis of five individual trials assessed factors
predicting nonhaematological toxicities in patients receiving
infused 5FU (Meta-analysis Group In Cancer, 1998b). However,
this study is limited as only 607 patients receiving infused 5FU
were included in the analysis, patients received a variety of
different schedules of infused 5FU and no data were provided
relating to the time course of toxicities.
This type of analysis is important as the more tolerable toxicity
profile of infused 5FU has led to greater interest in the use of this
schedule of administration. In advanced colorectal cancer, there
have been concerns relating to increased rates of early mortality
using bolus schedules of 5FU with irinotecan, which were not
observed using infused schedules (Douillard et al, 2000; Rothen-
berg et al, 2001). In addition, for adjuvant treatment of colorectal
cancer, there is increasing recognition that infused schedules of
5FU are as effective as bolus schedules, but with a lower incidence
of toxicity (Andre et al, 2002). PVI 5FU is also commonly used as a
component of treatment of advanced oesophago-gastric cancer
(Webb et al, 1997).
Baseline clinical factors associated with toxicity
Our analysis provides data relating to baseline clinical and
laboratory factors, which are associated with a greater risk of
developing moderate-to-severe toxicities. These include female
sex, older age and elevated ALT and urea for stomatitis and female
sex, better performance status and elevated bilirubin for PPE.
A previous analysis has suggested that good performance status
predicts superior response rates and more prolonged survival in
advanced colorectal cancer (Assersohn et al, 1999). Consequently,
factors such as better performance status are likely to indicate
those patients who are likely to have more prolonged progression-
free survival and who may therefore receive chemotherapy for
more protracted periods of time (Borner et al, 1998). The
association of better performance status with the development of
PPE has also been noted by other investigators (Meta-analysis
Group In Cancer, 1998b). However, the aim of this analysis was to
identify factors, which could be identified early during treatment,
which were independently associated with toxicity rather than
survival or response. Any decision about whether to use
chemotherapy inevitably involves a balanced judgement about
both the likely benefits of treatment as well as the risk of toxicity.
Other factors, such as female sex and age, are similar to those
found by other investigators who have demonstrated that bolus
schedules of 5FU caused more severe leucopenia in older female
patients and more severe stomatitis in older patients (Zalcberg
et al, 1998; Popescu et al, 1999). A recent analysis also
demonstrated that female patients suffered more severe toxicity
using bolus schedules of 5FU (Sloan et al, 2002). Older age and
female sex have also been previously associated with PPE using
infused 5FU (Meta-analysis Group In Cancer, 1998b).
The increased toxicity associated with 5FU administration in
older and female patients may reflect altered catabolism or
clearance of 5FU in these patients. More than 80% of an
administered dose of 5FU is eliminated by catabolism by the
enzyme dihydropyrimidine dehydrogenase (DPD). Severe 5FU
toxicity may occur in patients with partial or complete DPD
deficiency and these individuals show marked impairment of 5FU
clearance (Diasio et al, 1988; Lu et al, 1993; Milano et al, 1999).
Fluorouracil clearance has been shown to be impaired in females
although it does not appear to be affected by age (Milano et al,
1992).
Prediction of toxicity using DPD levels
On this basis, measurement of DPD levels has been suggested as a
possible method to identify patients at increased risk of 5FU
toxicity. However, there are limitations with such an approach.
Although the majority of 5FU is metabolised by the liver,
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Figure 3 (A) Time until initial development of varying grades of
stomatitis. (B) Proportion of patients receiving PVI 5FU with grade 2 or
worse stomatitis. Closed columns indicate patients with only grade X2
stomatitis, whereas open columns indicate patients with grade X2
stomatitis and grade X2 diarrhoea and/or PPE.
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lassessment of DPD levels is typically based on the levels of the
enzyme expressed in peripheral blood mononuclear cells because
of their easier accessibility. Unfortunately, assessment of periph-
eral blood DPD levels correlates only weakly with 5FU clearance
and is a poor predictor of 5FU toxicity (Fleming et al, 1992;
Etienne et al, 1994). Even among patients who had developed
severe 5FU toxicities, who might have been expected to be
relatively DPD deficient, only a proportion of patients had reduced
peripheral blood DPD levels (Milano et al, 1999; van Kuilenburg
et al, 2000). Therefore, measurement of DPD levels before 5FU
treatment has limited utility for the prediction of patients destined
to develop severe 5FU-related toxicities. This limitation may arise
because assessment of DPD levels in this fashion does not
accurately reflect the body’s capacity to metabolise 5FU or because
other factors may also predispose to 5FU toxicity.
Prediction of toxicity using pharmacokinetic monitoring
An alternative approach to predict and ultimately prevent severe
5FU toxicity is pharmacokinetic monitoring. Patients with DPD
deficiency may demonstrate a markedly altered pharmacokinetic
profile with significant reduction in the plasma levels of 5FU
metabolites. The impaired clearance of 5FU is thought to
contribute to its toxicity in these patients. Pharmacokinetic
evaluation provides a more direct information about whole-body
5FU catabolism, and small studies suggest that with infused 5FU,
higher plasma levels of 5FU correlate with increased toxicity
(Findlay et al, 1996; Gamelin et al, 1996). However, plasma 5FU
levels have been found to show wide inter- and intrapatient
variation and larger studies have failed to show any relation
between steady-state plasma 5FU levels and 5FU toxicity (Jodrell
et al, 2001). Thus, 5FU pharmacokinetic assessment is not
routinely used for the prediction of patients at increased risk of
toxicity.
Use of temporal factors in combination with baseline
clinical factors to assess risk of toxicity
This study provides a strong empirical basis for the use of
information about the temporal development of toxicity in
combination with baseline clinical factors in order to assess the
risk of toxicity. While it appears logical that patients who develop
early grade 1 toxicity would be at higher risk of developing a
subsequent more severe toxicity, the extent of the risk and the
possible implications for patient management have never pre-
viously been evaluated. Thus, the data suggest that older female
patients with good performance status and impaired liver function
who develop early grade 1 PPE or the combination of early grade 1
PPE and diarrhoea would be at a higher risk of grade 2 or worse
stomatitis and PPE. Such patients could receive a reduction in the
dose of 5FU at the time of development of early grade 1 toxicity,
which could prevent the development of more severe toxicity
altogether. This approach, if successful, would be likely to achieve
significant benefit in improvements in quality of life as well as
minimise treatment interruption due to toxicity.
However, in order to evaluate rigorously such an approach, it
will be important to validate the models generated in this study
prospectively. It will also be important to study the use of early
dose reduction for selected patients at high risk of toxicity
prospectively. This should involve assessment of response,
progression-free survival, overall survival and quality of life in
addition to toxicity outcomes in order to determine
whether efficacy and palliative benefit is affected using such an
approach.
Future applications
An increased understanding of factors associated with toxicity due
to chemotherapy may potentially allow early identification of
patients at risk of severe toxicity. This study suggests that
Table 3 Multivariate Cox regression analysis of factors predicting toxicity with PVI 5FU
Multivariate Cox regression
Factor Groups NP HR 95% CI of HR
Diarrhoea Xgrade 2
Early toxicity Early diarrhoea 196 0.008 1.541 1.121 2.119
No early diarrhoea 1172 1
PPE Xgrade 2
Performance status PS 0-1 1033 o0.001 1.692 1.302 2.199
PS 2-4 335 1
Sex Female 592 o0.001 1.413 1.173 1.700
Male 776 1
Bilirubin Low o12mmoll
 1 716 1
High X12mmoll
 1 652 0.001 1.357 1.127 1.635
Early toxicity Early PPE 218 o0.001 2.450 1.992 3.012
No early PPE 1150 1
Early diarrhoea 196 0.001 1.483 1.167 1.886
No early diarrhoea 1172 1
Stomatitis Xgrade 2
Sex Female 593 0.002 1.403 1.135 1.733
Male 776 1
Age Continuous 1369 0.002 1.016 1.006 1.026
ALT Low o16Ul
 1 683 0.002 1
High X16Ul
 1 686 1.390 1.126 1.717
Urea Low o4.8mmoll
 1 705 0.002 1
High X4.8mmoll
 1 664 1.422 1.143 1.769
Early toxicity Early PPE 218 o0.001 1.574 1.234 2.009
No early PPE 1151 1
Time course and prognostic factors for 5FU toxicity
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levaluation of the temporal pattern of toxicity can assist in this
process. Similar approaches using data derived from large patient
cohorts treated with other chemotherapy agents may allow
identification of prognostic factors, including temporal factors
associated with toxicity due to other drugs, which could prove
useful for clinical management.
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